Biogen’s monoclonal antibody felzartamab received its first global approval in China for multiple myeloma. The therapy is authorized for second-line use for patients treated alongside lenalidomide and the corticosteroid dexamethasone, expanding the set of antibody-linked regimens in the myeloma market. The authorization places felzartamab alongside existing standard-of-care backbone drugs in a setting where combinations and class differentiation are increasingly important for differentiation and sequencing. For Biogen, the China approval is also a meaningful market validation for its antibody portfolio in hematologic oncology. With approvals accumulating across multiple myeloma drug classes, the felzartamab decision underscores continued regulatory momentum for antibody-based strategies targeting distinct biological mechanisms within the disease.